<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic alterations, including methylation of key <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, may play a role in the progression of <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> to a castration-refractory state </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi>, an agent approved for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, appears to exert its <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> effects partly by hypomethylating DNA that leads to the reversal of gene silencing </plain></SENT>
<SENT sid="2" pm="."><plain>It is hypothesized that the addition of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> to complete <z:chebi fb="3" ids="50113">androgen</z:chebi> blockade may restore the responsiveness of progressive <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> to hormonal therapy </plain></SENT>
<SENT sid="3" pm="."><plain>A phase II trial was designed to evaluate the activity of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> to primarily modulate PSA kinetics, with supportive secondary clinical endpoints </plain></SENT>
<SENT sid="4" pm="."><plain>Correlative studies will be performed to detect the biologic activity of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (increased fetal <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, plasma DNA methylation) and examine any association with anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> clinical activity </plain></SENT>
</text></document>